ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2422

Anti-P. Gingivalis antibody Is Correlated With Severity Of Periodontitis But Not With Rheumatoid Arthritis Disease Activity In RA

Joo Youn Lee1, In Ah Choi2, Jin-Hee Kim3, Kyung-Hwa Kim4, Hye Jin Oh5, Myeong Jae Yoon6, Eun Young Lee2, Eun Bong Lee2, Yong-Moo Lee3 and Young Wook Song1,2, 1Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 3Department of Periodontology, School of Dentistry, Seoul National University, Seoul, South Korea, 4Department of Periodontology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, South Korea, 5Seoul National University, Seoul, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Periodontitis

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Periodontitis (PD) has been suggested to be one of risk factors for rheumatoid arthritis (RA). Porphyromonas gingivalis (P. ginvivalis, Pg) is a gram-negative anaerobic bacterium that is recognized as a major pathogenic organism in periodontitis (PD). Anti-enolase 1 (ENO1) antibody is one of the autoantibodies in RA. / This study examined the relationship between serum levels of anti-Pg and anti-ENO1 antibodies and PD severity and RA disease activity in patients with RA.

Methods: 248 Patients with RA and 85 age-, sex- matched non-RA controls were enrolled in this study. After rheumatologic and periodontal examination, serum levels of anti-Pg antibodies and anti-ENO1 antibodies were measured by enzyme-linked immunosorbent assay (ELISA).

Results: Patients with RA showed significantly higher levels of anti-Pg antibodies and, anti-ENO1 antibodies than controls (P= 0.0082, P< 0.0001). Anti-Pg antibodies were strongly correlated with anti-ENO1 antibodies in RA patients (p<0.0001). In active RA, there were significant correlations between anti-Pg antibodies with probing pocket depth (PPD), bleeding on probing (BOP) and clinical attachment level (CAL) (P= 0.0015, P=0.006, P=0.0004). However, there were no correlations of anti-Pg antibodies and periodontal parameters in controls and inactive RA. Anti-ENO1 titer did not correlate with periodontal parameters except bleeding on probing (BOP) in RA. Anti-Pg antibodies were not correlated with RA disease activity except ESR (p= 0.0175). However anti-ENO1 antibodies were significantly correlated with ESR, DAS28-ESR, anti-CCP titer (P= 0.0008, P= 0.0092, P= 0.0129).

Conclusion:  Anti-Pg antibodies and anti-ENO1 antibodies were elevated in RA patients than controls. Anti- Pg antibodies were correlated with severity of PD and anti-ENO1 antibodies were correlated with RA disease activity in RA patients.


Disclosure:

J. Y. Lee,
None;

I. A. Choi,
None;

J. H. Kim,
None;

K. H. Kim,
None;

H. J. Oh,
None;

M. J. Yoon,
None;

E. Y. Lee,
None;

E. B. Lee,
None;

Y. M. Lee,
None;

Y. W. Song,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-p-gingivalis-antibody-is-correlated-with-severity-of-periodontitis-but-not-with-rheumatoid-arthritis-disease-activity-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology